Recent clinical success of T cell-based cancer immunotherapy [21]–[27] has resulted in a surge in demand for the pmel-1 mouse as an ideal model system to study the mechanism of tumor immunology, CD8+ T cell differentiation, and adoptive immunotherapy [28]–[59]. Here, CD8A is linked to neoplasm.